Latest Trials Latest NewsFAQ

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Phase 2

Conditions: Thrombopenia
Recurrent Colorectal Carcinoma

Interventions: Drug: rhTPO
Drug: irinotecan
Drug: Raltitrexed
Radiation: radiotherapy
Drug: rhIL-11

First Posted Date: 2019-01-30

Last Posted Date: 2019-01-30

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT03823079

FUSCC Refractory TNBC Umbrella (FUTURE)

Phase 1

Conditions: Triple-negative Breast Cancer

Interventions: Drug: MES with anti-VEGFR included therapy
Drug: Pyrotinib with Capecitabine
Drug: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)
Drug: PARP inhibitor included therapy
Drug: anti PD-1 with nab-paclitaxel
Drug: BLIS with anti-VEGFR included therapy
Drug: mTOR inhibitor with nab-paclitaxel

First Posted Date: 2019-01-15

Last Posted Date: 2022-08-10

Lead Sponsor: Fudan University

Target Recruit Count: 140

Registration Number: NCT03805399

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Phase 4

Conditions: HER-2 Negative Breast Cancer

Interventions: Drug: Chemotherapy

First Posted Date: 2019-01-10

Last Posted Date: 2019-01-10

Lead Sponsor: Fudan University

Target Recruit Count: 78

Registration Number: NCT03799692

Locations: 🇨🇳
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Phase 4

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Chemotherapeutic Agent

First Posted Date: 2019-01-10

Last Posted Date: 2019-01-10

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT03799679

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Irinotecan
Drug: DDP
Drug: Endostar

First Posted Date: 2019-01-09

Last Posted Date: 2019-01-09

Lead Sponsor: Fudan University

Target Recruit Count: 76

Registration Number: NCT03797625

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer

Not Applicable

Conditions: Pancreatic Cancer
Laparoscopy
Surgery

Interventions: Procedure: Laparoscopic distal pancreatectomy
Procedure: Open distal pancreatectomy

First Posted Date: 2019-01-04

Last Posted Date: 2022-06-22

Lead Sponsor: Fudan University

Target Recruit Count: 306

Registration Number: NCT03792932

Locations: 🇨🇳
Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
🇨🇳
Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University,, Harbin, Heilongjiang, China

and more 8 locations

Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Phase 3

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: Radiotherapy

First Posted Date: 2018-12-31

Last Posted Date: 2023-08-03

Lead Sponsor: Fudan University

Target Recruit Count: 646

Registration Number: NCT03790553

Locations: 🇨🇳
Huadong Hospital, Shanghai, Shanghai, China
🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

CD155 in Bladder Cancer

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Adjuvant chemotherapy

First Posted Date: 2018-12-28

Last Posted Date: 2020-02-05

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT03789682

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Short-term Health Benefits of Using Fresh Air Filtration System in Classroom

Not Applicable

Completed

Conditions: Airway Morbidity
Oxidative Stress
Cognitive and Attention Disorders and Disturbances

Interventions: Device: Fresh air system with filtration

First Posted Date: 2018-12-27

Last Posted Date: 2019-03-29

Lead Sponsor: Fudan University

Target Recruit Count: 94

Registration Number: NCT03788330

Locations: 🇨🇳
Fudan University, Shanghai, China

Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.

Conditions: Colorectal Cancer Stage I-IV

Interventions: Diagnostic Test: CT or MRI based Radiomics

First Posted Date: 2018-12-26

Last Posted Date: 2018-12-26

Lead Sponsor: Fudan University

Target Recruit Count: 2000

Registration Number: NCT03787667

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy